In the years 2016 to 2020, over 99 percent of patients diagnosed with melanoma of the skin in England aged between 15 and 44 years of age would survive for at least one year, while patients this age had a five-year survival rate of nearly 97 percent. The survival rates for melanoma of the skin did generally fall if the patient was older when diagnosed.

Mortality from skin cancers other than malignant melanoma (ICD-10 C44 equivalent to ICD-9 173). To reduce deaths from skin cancers other than malignant melanoma. Legacy unique identifier: P00652

In the period 2013 to 2017, almost 99 percent of those aged between 15 and 44 years who were diagnosed with melanoma skin cancer in England survived for at least one year after being diagnosed, while over 96 percent in this age group survived for five years. Over the period provided, the older age groups have a lower survival rate than the younger age groups.

Legacy unique identifier: P00657

Around 69 in every 100,000 Australians were projected to be diagnosed with melanoma, a type of skin cancer, in 2023. The incidence rate increased with age, with the 85-89-year-old age group having an estimated incidence of over 290 cases per 100,000 persons in 2023.

Incidence of cancer in Australia

Cancer incidence refers to the number of newly diagnosed cases of the disease in a particular time period, typically one year. Cancer is among the leading causes of illness and death in Australia. The types of cancer with the highest incidence in Australia include prostate, breast, colorectal/bowel, melanoma, and lung cancer.

The dark side of the sunny life Down Under

Australia and New Zealand are home to the highest incidence rates of melanoma in the world. Melanoma is a type of skin cancer that is commonly, however not exclusively, found on sun-exposed parts of the body, as the risk of developing melanoma increases with ultra-violet radiation (UV rays). Other types of skin cancers exist, however, melanoma is considered to be the most dangerous given its likelihood of spreading within the body.

In 2020, the mortality rate for melanoma cancer was 1.8 per 100,000 population among females in Canada. This statistic displays the age-standardized mortality rate of melanoma among females in Canada between 1988 and 2020, with forecasts from 2021 to 2023.

Legacy unique identifier: P00645

In 2020, the mortality rate for melanoma was 3.5 per 100,000 population among males in Canada. This statistic displays the age-standardized mortality rates of melanoma among males in Canada between 1988 and 2020, with forecasts from 2021 to 2023.

This statistic shows the amount of registrations of newly diagnosed cases of skin cancer in England in 2022, by age group and gender. Almost 1.5 thousand new cases were recorded among men aged 75 to 79 years of age. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to skin cancer.

IntroductionThe incidence of melanoma has been increasing in the last decades. A retrospective Hungarian epidemiological study provided real-world data on incidence and mortality rates. There have been changing trends in incidence in Hungary in the last decade and mortality decreased, shifting mortality-to-incidence rate ratios (MIR). MIR is an indicator of cancer management quality.ObjectivesOur aim is to show the changes of melanoma MIR in Hungary between 2011 and 2018 and to compare the real-world evidence-based results of our Hungarian nationwide retrospective study with other European countries.MethodsMIR is calculated from the age-specific standardized incidence and mortality rates from our study. Annual MIR values are presented for the total population and for both sexes between 2011 and 2018, along with 95% confidence intervals. Comparison with European countries are shown for 2012 and 2018 based on the GLOBOCAN database and Eurostat health care expenditure per capita data.ResultsMIR decreased by 0.035 during the study years. The decrease was same in both sexes (0.031). Male had higher MIRs in all study years. In both 2012 and 2018, Hungarian MIR in both sexes was lower than the European Union average (males: 0.192 vs. 0.212 and 0.148 vs. 0.174 respectively, women: 0.107 vs. 0.129 and 0.083 vs. 0.107 respectively).DiscussionHungarian mortality-to-incidence ratio is the lowest in Central and Eastern Europe and is close to the level of Western and Northern European countries. The results are driven by the high number of new diagnosed melanoma cases.

In 2022, the incidence of melanoma skin cancer cases was the highest among those aged above 75 years of age in the European Union. As a matter of fact, the risk of developing skin cancer can increase as a person ages due to the accumulation of exposure to UV radiation from the sun. This statistic shows the incidence of melanoma skin cancer in the European Union in 2022, by age and gender.

This statistic shows the number of deaths from melanoma skin cancer in Australia in 2016, by age group. That year, around 276 people aged 85 years and older died from melanoma skin cancer in Australia.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

For current version see: https://data.sandiegocounty.gov/Health/2021-Non-Communicable-Chronic-Diseases/v7dt-rwpx

Basic Metadata *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

This study aims to provide a comprehensive overview of sex-related characteristics of cutaneous malignant melanoma (CMM), with special reference to its incidence, clinicopathological profile, overall survival, and treatment-related costs. This retrospective cohort study included all 1,279 CMM patients who were registered in 2015 in the Veneto Cancer Registry (a population-based registry including all 4,900,000 regional residents). The by-sex comparisons included tumor stage and site, histological subtype, and other clinical-pathological variables. A Cox regression analysis was used to test the association between sex and survival, adjusting for the main covariates. Treatment costs were calculated by linking patients with several administrative regional databases. Age-specific incidence rates were significantly higher for men among people >50 years old. For men, the trunk was the most common primary site (59.3%), whereas for women the lower limbs (32.1%) were the most common primary site, followed by the trunk (31.8%), which was lower than for men (p < 0.001). At presentation, the frequency of early stage CMM was higher among women, who also featured a significantly lower risk of death (p = 0.016), after adjusting for covariates. Men also incurred higher costs for melanoma treatment in the first year after their diagnosis. Among younger adults, CMM was more common in women, whereas among older adults, it was more common in men. Sex also influences patients' histopathological characteristics at diagnosis. Women had better overall survival after adjusting for demographic, pathological, and clinical profiles. The costs of treatment were also lower for women with CMM.

This data was taken from the R `lattice' package. The data is described in the package as follows: These data from the Connecticut Tumor Registry present age-adjusted numbers of melanoma skin-cancer incidences per 100,000 people in Connecticut for the years from 1936 to 1972. Format: A csv file has 37 observations on the following 2 variables. year: years 1936 to 1972. incidence: rate of melanoma cancer per 100,000 population.

In the period 2013 to 2017, every person who was diagnosed with stage one melanoma skin cancer in England survived for at least one year after being diagnosed, while over 99.6 percent survived for five years. This highlights the importance of detecting cancers early. In individuals diagnosed with stage four skin cancer, 53 percent survived for at least one year.

In 2022, the number of new skin melanoma cases in England was 35.5 per 100,000 for males and 29 per 100,000 for females. This marked the highest rate of newly diagnosed malignant melanoma cases for both genders during the analyzed years. This statistic shows the rate of newly diagnosed cases of skin melanoma cancer per 100,000 population in England from 1995 to 2022, by gender.

The global skin cancer treatment market, valued at $13.82 billion in 2025, is projected to experience robust growth, driven by rising skin cancer incidence rates worldwide, an aging global population increasing susceptibility, and growing awareness regarding early detection and treatment. Technological advancements in diagnostic tools like dermatoscopy and genetic testing, coupled with the development of innovative therapeutic approaches such as immunotherapy and targeted therapy, are significantly contributing to market expansion. The market is segmented by cancer type (melanoma and non-melanoma) and treatment type (diagnosis and therapeutics), with melanoma representing a substantial portion due to its aggressive nature and higher treatment costs. North America currently holds the largest market share, attributed to advanced healthcare infrastructure, high prevalence of skin cancer, and increased spending on healthcare. However, the Asia-Pacific region is expected to witness significant growth in the coming years, driven by rising disposable incomes, increased healthcare awareness, and expanding healthcare infrastructure in developing economies. While effective treatments are available, limitations such as high treatment costs, potential side effects of certain therapies, and lack of access to advanced healthcare in under-resourced regions pose challenges to market growth. The competitive landscape features major pharmaceutical companies and diagnostic providers actively engaged in research and development, further fueling market expansion. The forecast period of 2025-2033 anticipates a continuation of this growth trajectory. The 5.21% CAGR suggests a considerable market expansion, influenced by factors such as ongoing research leading to more targeted and effective treatments, improvements in early detection strategies, and broader access to healthcare in emerging markets. However, the market will continue to navigate challenges like the price sensitivity of certain therapies and the need for sustained investment in research and development to address treatment limitations and enhance patient outcomes. The continued development and adoption of innovative therapies, alongside improvements in diagnostic capabilities, will be key drivers of future market growth. Competition among established players and emerging biotech companies will intensify, further shaping the market landscape in the coming years. Recent developments include: In March 2022, the United States Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab., In January 2022, SkinCure Oncology focused on providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy (Image-Guided SRT) and launched GentleCure.com, a consumer health education platform offering evidence-based treatment options for basal cell (BCC) and squamous cell skin cancers (SCC).. Key drivers for this market are: Increasing Incidence of Skin Cancer, Rising Awareness About Skin Cancer; Extensive Research and Developments. Potential restraints include: Increasing Incidence of Skin Cancer, Rising Awareness About Skin Cancer; Extensive Research and Developments. Notable trends are: Non-Melanoma by Cancer Type Segment is Expected to Grow Over the Forecast Period.

Non-melanoma Skin Cancer Drugs Market Outlook

The global non-melanoma skin cancer drugs market size was valued at approximately USD 1.2 billion in 2023 and is projected to reach around USD 2.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This promising growth is largely driven by the increasing prevalence of non-melanoma skin cancers, the aging global population, and advancements in cancer treatment technologies. As awareness about skin cancer increases and more effective treatment options become available, the market is expected to see substantial growth.

One of the primary growth factors for the non-melanoma skin cancer drugs market is the rising incidence of skin cancer worldwide. Non-melanoma skin cancers, which include Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), are among the most common types of skin cancer. The increasing exposure to ultraviolet (UV) radiation, both from natural sunlight and artificial sources like tanning beds, has significantly contributed to the surge in skin cancer cases. Additionally, advancements in diagnostic techniques have led to early detection and treatment of these cancers, further driving the demand for effective pharmaceutical solutions.

Another significant growth factor is the aging population globally. As people age, their risk of developing skin cancer increases due to cumulative exposure to UV radiation over their lifetime. The elderly population is more susceptible to skin damage, and consequently, the incidence of non-melanoma skin cancers is higher in this demographic. This demographic shift is expected to be a major driver for the market, as healthcare systems and pharmaceutical companies focus on developing and providing effective treatments for this age group.

In addition to non-melanoma skin cancers, the market for Melanoma Drugs is also experiencing significant growth. Melanoma, although less common than basal cell carcinoma and squamous cell carcinoma, is a more aggressive form of skin cancer. The development of novel therapies, including targeted treatments and immunotherapies, has been pivotal in improving outcomes for melanoma patients. These advancements have led to increased survival rates and a better quality of life for those affected by this serious condition. The focus on personalized medicine and the identification of specific genetic mutations in melanoma cells have further enhanced the effectiveness of these treatments, making them a critical component of the broader skin cancer drugs market.

Technological advancements in cancer treatment, including the development of targeted therapies and immunotherapies, have also played a crucial role in the market's growth. Recent innovations have led to the creation of more effective and less invasive treatment options, which not only improve patient outcomes but also reduce the side effects associated with traditional chemotherapy. These advancements have made it possible to tailor treatments to individual patients, enhancing the efficacy and tolerability of non-melanoma skin cancer drugs.

The regional outlook for the non-melanoma skin cancer drugs market highlights significant growth opportunities across various geographies. North America, particularly the United States, currently holds the largest market share due to high awareness levels, advanced healthcare infrastructure, and substantial R&D investments. Europe is also a major market, driven by similar factors. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, fueled by increasing healthcare expenditure, rising awareness about skin cancer, and improving healthcare infrastructure. Latin America, and the Middle East & Africa regions are also expected to show substantial growth due to improving healthcare access and rising incidence rates.

Drug Type Analysis

The non-melanoma skin cancer drugs market is segmented by drug type into topical treatments, chemotherapy, immunotherapy, targeted therapy, and others. Topical treatments, including creams and ointments, are commonly used for treating early-stage non-melanoma skin cancers. These treatments are often preferred due to their ease of application and minimal side effects. They work by directly targeting the affected area, reducing the risk of systemic side effects. The demand for topical treatments is expected to remain strong, driven by their effectiveness and convenience.